EpiVario, Inc.

Company to receive over $250,000 in research funding to address condition affecting more than 14 million U.S. adults PHILADELPHIA, Sept. 13, 2022 /PRNewswire/ -- EpiVario, Inc., a biotech company developing novel therapeutics for memory-related psychiatric disorders, today announced it has been awarded a grant of nearly $260,000 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to advance research on its proprietary small molecule inhibitors designed to reduce alcohol craving responses and help people with alcohol use disorder prevent relapse. Alcohol Use Disorder (AUD) is characterized by an impaired ability to stop or control alcohol use despite clinically significant impairment, distress, or other adverse consequences. As one of the most common substance use disorders, it costs the U.S. healthcare system roughly $28 billion annually, and contributes to over 95,000 deaths each year. Moreover, alcohol use and misuse are thought to contribute to over 200 related diseases and health conditions globally, including cardiovascular disease, cancer, liver cirrhosis, and injuries1. The current standard of care for AUD is a combination of detoxification, psychotherapy, and community support programs, such as Alcoholics Anonymous. The limited number of pharmacotherapeutics available to supplement such treatments are not uniformly effective and are hampered by side effects, creating an urgent need for more effective treatments. EpiVario has developed an epigenetic approach to AUD that controls neuronal plasticity, inhibiting alcohol-related memory processes, which are known to play a large role in driving the disorder. The metabolic enzyme ACSS2 generates acetyl-CoA, a key cofactor for patterns of histone acetylation important for long-term memory2. EpiVario's co-founders, Drs. Shelley Berger and Philipp Mews, discovered that ACSS2 plays a critical role in alcohol-related learning by coordinating alcohol-induced histone acetylation and gene expression in the hippocampus, which converts alcohol-derived acetate to acetyl-CoA3. This supports the hypothesis that alcohol may exert its addictive properties via ACSS2-dependent histone acetylation. This novel gene regulatory mechanism presents an attractive therapeutic strategy via pharmacological inhibition of ACSS2 to interfere with alcohol-related learning that drives AUD. EpiVario's research will continue to evaluate the company's existing collection of small molecule inhibitors of ACSS2 for safety and efficacy in vivo, validate ACSS2 as a therapeutic target, and establish ACSS2 inhibition as a potential novel therapeutic strategy to treat AUD. "This award marks a significant milestone for both our company and the millions affected by alcohol addiction worldwide," said Thomas Kim, President & CEO of EpiVario. "We are one step closer to addressing the urgent need for a reliable and safe AUD pharmacotherapy with minimal side effects. We are excited to deploy this funding to advance our preclinical research and aspire to begin human trials by the first half of 2024." Dr. Howard Becker, Professor at the Medical University of South Carolina (MUSC), is widely recognized for his development of relevant animal models of AUD and their use in research on mechanisms and strategies for treating excessive, harmful drinking. In collaboration with MUSC, Dr. Becker was selected as Principal Investigator for EpiVario's six-month study. "I am honored to work with EpiVario on this truly innovative science," said Dr. Becker. "I have previously collaborated with EpiVario and its cofounder, Dr. Mews, and I am now most happy to collaboratively work on advancing EpiVario's drug development program that embraces a therapeutic strategy which is unlike any other AUD treatment available. It is exciting to take an active role in bringing this potentially life-changing therapy to market." The isolation and stress of the pandemic has only worsened alcohol addiction over the past few years, and it's estimated that binge drinking increased by 21% since 20204. Alcohol consumption changes due to COVID-19 are expected to cause 100 additional deaths and 2,800 additional cases of liver failure by 2023. While the number of affected people continues to rise, only approximately 7% of people who had AUD in the past year received any treatment. About EpiVario, Inc. EpiVario is a biotech company developing novel therapeutics to address a wide range of memory-related psychiatric disorders, including PTSD, Alzheimer's, and alcohol and drug addiction. EpiVario's strategy is to treat these psychiatric disorders at the source of the disease – the intrusive memories that often cause relapse. These memories are weakened via epigenetic regulation through the target enzyme acetyl-coA synthetase 2 (ACSS2), which regulates consolidation of fear and drug-craving memories. EpiVario's co-founders discovered that ACSS2 is a key metabolic enzyme that works directly within the nucleus of neurons to turn genes on when new memories are being established, and also when memories are recalled and then reconsolidated. For more information visit . Media Contact: Alyson Kuritz [email protected] (908) 892-7149 Burnette, E. M. et al. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. Drugs 82, 251–274 (2022). Mews, P. et al. Acetyl-CoA synthetase regulates histone acetylation and hippocampal memory. Nature 546, 381–386 (2017). Mews, P. et al. Alcohol metabolism contributes to brain histone acetylation. Nature (2019) doi:10.1038/s41586-019-1700-7. The effect of COVID-19 on alcohol consumption, and policy responses to prevent harmful alcohol consumption. . SOURCE EpiVario Inc.

In vivo preclinical research findings from EpiVario and its co-founders describe a novel approach for reducing fear memories, which underly Post-Traumatic Stress Disorder PHILADELPHIA, Aug. 22, 2022 /PRNewswire/ -- EpiVario, Inc., an emerging biotech company developing novel therapeutics for memory-related psychiatric disorders, today highlighted preclinical research findings that could lead to a treatment approach for PTSD. Published in Proceedings of the National Academy of Sciences (PNAS), and co-authored by the academic co-founders of EpiVario, the study demonstrates that fear memories can be controlled through the enzyme acetyl-CoA synthetase 2 (ACSS2). The team also confirmed that a small molecule inhibitor against ACSS2 can block the epigenetic process required for the consolidation of stress and fear memories. Continue Reading In the study, published online August 5th in PNAS, the researchers identified the metabolic enzyme ACSS2 as a key regulator of fear memory, and showed that genetic deletion or pharmaceutical inhibition of ACSS2 greatly reduces the ability of mice and rats to form long-term memories of trauma events. The study demonstrates that fear memories can be controlled through the enzyme acetyl-CoA synthetase 2 (ACSS2). Tweet this The study was conducted at the Perelman School of Medicine at the University of Pennsylvania and was led by EpiVario Co-Founder Shelley Berger, PhD, Daniel S. Och University Professor and Director of the Penn Epigenetics Institute, and Co-Founder Philipp Mews, PhD, currently an Instructor at The Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai in New York, along with Tanya Corman, PhD, a postdoctoral scientist at University of Pennsylvania. Investigational small molecule compounds were provided by EpiVario, which is developing ACSS2 inhibitors as a therapeutic for memory related neuropsychiatric disorders. This work was further enabled through EpiVario collaborators Dr. Marcelo Wood at UC Irvine, and Dr. Hagit Cohen at Ben-Gurion University of the Negev, Israel. "These new results are exciting, as they validate our earlier discovery that ACSS2 is critical for activating genes during the creation of fear memories. Similarly, whenever we recall a traumatic event, these genes are activated in the same way, a process called reconsolidation, which is important in PTSD. In principle, reducing that reconsolidation by briefly blocking ACSS2, we expect to weaken trauma memories that underlie PTSD," said Dr. Mews. Previous research conducted in Berger's lab, and led by Dr. Mews, found that ACSS2 is a key metabolic enzyme that works within the nucleus of neurons to turn genes on when new memories are being established, and also after older memories are recalled (Mews et al., Nature 2017 & 2019). ACSS2 catalyzes the production of acetyl-coenzyme A (acetyl-CoA), a small molecule that serves as a cellular carrier of a chemical tag called acetyl group. Among its many actions, acetyl-CoA uses its acetyl payload to carry out a process called histone acetylation, which controls gene activity—including the gene activity needed to turn short-term memories into long-term memories. In the present study, the researchers investigated ACSS2's role in forming long-term fear memories in adult mice. The team first developed a line of mice in which the ACSS2 gene was disabled. They found that the absence of the gene did not impair ordinary, short-term working memory or other mouse activities, but did significantly reduce the strength of long-term memories, including fear memories. The researchers also confirmed a reduction of histone acetylation and gene activity changes normally associated with long-term memory consolidation. "These new findings support our approach of inhibiting ACSS2 as a therapeutic target to potentially reduce stress associated with traumatic memory," said Dr. Berger, senior author of the study. Next, the team injected normal mice and rats, immediately before and after fear-conditioning, with a compound that blocks ACSS2 activity for a brief period of time. Compared to untreated rodents, the treated animals showed significantly less freezing behavior when presented with shock-reminder cues. Importantly, the effect of the inhibitor was specific to gene activity during the treatment period—drug administered outside the consolidation window had no impact on the strength of memories formed. Lastly, the scientists used a rat model of PTSD, in which rats are exposed to a predator scent (cat urine) and tested a week later for heightened signs of anxiety when exposed to the scent. Here again, the presence of the ACSS2 inhibitor during the memory-consolidation window reduced subsequent anxiety signs in the treated rats, compared to control rats. "These research findings continue to encourage the team at EpiVario, since they provide significant additional in vivo validation of EpiVario's therapeutic approach, and further underscore the importance of ACSS2 as a target for attenuating fear memories, which we believe could be a transformative approach for the treatment of PTSD," said Thomas Kim, President and CEO of EpiVario. "It is exciting to see EpiVario's work progress through targeting fear-related neuroplasticity and the formation of fear memories," said Dr. John Krystal, EpiVario SAB member, and Chair of Psychiatry at Yale University. "We urgently need new treatments for PTSD, and need to explore innovative new therapeutic strategies, with ACSS2 inhibition representing a novel strategy that holds significant promise." EpiVario exclusively in-licensed the intellectual property related to this work from the University of Pennsylvania. In addition to their current work on the development of a treatment for PTSD, EpiVario is developing small molecule therapeutics for alcohol and substance use disorders, which, akin to the roots of PTSD, emerge from learned behaviors embedded in memory. University of Pennsylvania financial disclosure Dr. Berger is a Penn faculty member, as well as a scientific collaborator, advisor, and co-founder of EpiVario. As such, she holds an equity stake in the company, her laboratory at Penn receives sponsored research funding from EpiVario, and as an inventor of certain Penn intellectual property that is licensed to Epivario, she and Penn may each receive additional financial benefits in the future. Penn also holds a founder's equity stake in the company. About EpiVario, Inc. EpiVario is an emerging biotech company developing novel therapeutics to address a wide range of memory-related psychiatric disorders, including PTSD, Alzheimer's, and alcohol and drug addiction. EpiVario's strategy is to treat these psychiatric disorders at the source of the disease – the intrusive memories that often cause relapse. These memories are attenuated via epigenetic regulation through the target enzyme acetyl-coA synthetase 2 (ACSS2), which regulates consolidation of fear and drug-craving memories. EpiVario's co-founders discovered that ACSS2 is a key metabolic enzyme that works directly within the nucleus of neurons to turn genes on when new memories are being established, and also when memories are recalled and then reconsolidated. For more information visit . Media Contact: Thomas Kim [email protected] 215-400-0133 SOURCE EpiVario Inc.

The MedCity INVEST Precision Medicine healthcare conference on December 9-11 draws healthcare and life science executives and investors as we spotlight progress in the development of diagnostics, clinical trial innovation, AI in drug development, and reimbursement models for cell and gene therapy. To view the full agenda, click here. To register, click here. 10:30 AM–11:30 AM ET: Clinical Trial Design Trends Remote monitoring for clinical trials has the potential to transform clinical trial design, enabling a more diverse pool of participants, potentially easing recruitment obstacles and help patients fit participation into their lifestyles. How far have we come since Pfizer’s first remote monitoring pilot? Which technologies/use cases are proving effective? What are some of the challenges ahead? Moderator: Frank Vinluan, Business Journalist Speakers: Peyton Howell, EVP and Chief Commercial & Strategy Officer, Parexel Viraj Narayanan, Vice President, Life Sciences & Strategic Partnerships, COTA Clay Williams, Founder/CEO, Medaptive Health, Inc. 12:30 –1:30 PM ET: Investment Trends in Precision Medicine Join us for a discussion on investments year-to-date for health-tech and life science companies and the impact of M&A deals from 2019. How have investment strategies and priorities changed? How do they work with startups/growth stage companies? How are strategic investors changing the investment landscape? What have they learned from investment missteps and successes? Moderator: Peter Micca, Partner, Deloitte Speakers: Julie Grant, General Partner, Canaan Jeffrey Low, M.D., Principal, Novo Growth Christopher McFadden, Managing Director, KKR Credit 2:30–4:00 PM ET Pitch Perfect: Presentations from Life Science Startups Life Science companies share different approaches to addressing some of the pain points in healthcare. Each startup with have 4 minutes to pitch followed by 6 minutes of Q&A with the judges. Biomeme’s end-to-end mobile platform empowers users to take real-time PCR everywhere they need it, from sample collection to data management. The company started out by creating the first iPhone add-on capable of performing molecular diagnostics. Since its inception, Biomeme has used advanced biology and chemistry along with world-class hardware and software engineering to create elegant solutions to complex problems. Over the years its team has grown, and along the way Biomeme has built the leading mobile molecular diagnostics platform. CEO: Max Perelman Headquarters: Philadelphia, PA EpiVario is a preclinical stage biotechnology company that is developing neuroepigenetic modulators to treat memory related psychiatric disorders. The company’s newly discovered epigenetic regulatory mechanism provides a target for treating memory-related neuropsychiatric disorders, since it plays a critical role in consolidating trauma-induced fear and stress responses, in addition to cue-induced craving that underlies various addiction disorders. Based on this paradigm-shifting finding, EpiVario is developing pharmacotherapeutics to treat anxiety and addiction disorders, including PTSD and alcohol use disorder. CEO: Thomas Kim Headquarters: Philadelphia, PA Gregor Diagnostics is a molecular diagnostics company focused on developing a new screening test for prostate cancer. Prostate cancer screening has been a hotly debated topic over the last two decades because of the overdiagnosis and overtreatment caused by current screening methods. Gregor is developing a better solution that can limit these issues, while still saving men from this deadly disease. CEO: Tobias Zutz Headquarters: Madison, WI SOLUtion is an early-stage life science company developing more patient friendly drug delivery systems for reconstitutable drugs. We specifically aim to improve the administration efficacy of life-saving injectable medication with our TwistJect auto-injector for people living with adrenal insufficiency including Addison’s Disease and Congenital Adrenal Hyperplasia. CEO: Julia Anthony Headquarters: Philadelphia, PA Stingray Therapeutics is an immune oncology company leading the charge to bring the next generation of new immune oncology agents forward. Today, all our immune oncology therapeutics are in only one arm of the immune system – adaptive immunity. But the immune system has two major arms that synergistically work together, adaptive and innate immunity. The company’s program in innate immunity inhibits the direct negative regulator of the major pathway, adding innate immunity into the fight against cancer, and has the promise of making immune oncology therapy dramatically more effective. CEO: Jonathan Northrup Headquarters: Houston, TX TrialSpark is a technology company that helps bring treatments to patients faster. Today, clinical trials are the bottleneck to bringing life-saving treatments to patients. Trials are slow, inefficient, and expensive. TrialSpark believes that it can use technology to accelerate the pace of clinical trials and bridge the gap between medical research and patients who need treatment. Client Growth Director: Joe Zaccaria Headquarters: New York, NY Judges: Wayne Barz is Chief Investment Officer, Ben Franklin Technology Partners – Northeast PA Rena Rosenberg is a Partner with Robin Hood Ventures